



Anticancer Nanomedicine: Recent Advances

Guest Editor:

Dr. Maria de la Fuente

Nano-Oncology and
Translational Therapeutics Unit,
Health Research Institute of
Santiago de Compostela (IDIS),
Clinical University Hospital of
Santiago de Compostela (CHUS),
CIBERONC, 15706 Santiago de
Compostela, Spain

Deadline for manuscript
submissions:

closed (31 March 2021)

Message from the Guest Editor

Dear Colleagues,

Cancer continues to be one of the main causes of death worldwide. A concerted effort in research is urgently needed to decrease the health and socioeconomic impact of cancer. Nowadays, it is known that nanomedicine can contribute to the development of advanced and more efficient therapeutics, helping to fight cancer by providing improved outcomes in terms of toxicity and overall survival. Recent advances regarding the role of the tumor microenvironment and the immune system in cancer progression and formation of metastasis have prompted the development of new nanomedicines specifically designed to target cell populations other than cancer cells, as well as the development of combinatory treatments to provide a holistic approach. In parallel, nanomedicine can contribute to the development of innovative diagnosis modalities for the early detection of cancer and follow-up, as well as more advanced nanotheranostics. This Special Issue aims to incorporate a summary of up-to-date articles to provide a comprehensive overview of the most recent advances in cancer nanomedicine.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,
Ernest Mario School of
Pharmacy, Rutgers University,
Piscataway, NJ 08854, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Contact Us

Pharmaceutics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
X@MDPIpharma